Leading today's oncology KOL conversation on X: First-line daraxonrasib data at ENA26; TroFuse-015 meets OS. The KOL Pulse Daily Digest: what verified physician voices are discussing on X across the major tumor types, ranked by engagement over the last 48 hours.
Yakup Ergün · @dr_yakupergun“First-line daraxonrasib + gem/nab-paclitaxel in metastatic pancreatic cancer (Ph 1/2, n=61): • ORR: 60.7% (CR: 8.2%) • mPFS: 12.8 mo • 12-month OS: 76.6% With standard chemotherapy combinations, ORR is approximately 36–42%, mPFS 5.6–7.4 mi, and mOS 9–11 months. These results are highly promising. The definitive comparison will come from the Phase 3 RASolute 303 trial, but even these early data may herald a major breakthrough in pancreatic cancer. Let's also remember that, although daraxonrasib monotherapy received FDA approval in the second-line setting, it is also approved for first-line use in patients with metastatic disease who are not candidates for multiagent chemotherapy. https://t.co/I9bRm0ZhEW”
View post ↗Full GI Cancers coverage in today's digest →Dr. Patrick Forde presented phase 1 results of BioNTech's investigational mRNA tumor-associated antigen vaccine BNT116, with or without cemiplimab, in advanced NSCLC at #ENA26, citing efficacy signals in frail first-line patients and after prior PD-1 therapy, with cohorts including oncogene-driven tumors ongoing. Dr. Yakup Ergün highlighted a study linking regular alcohol use to shorter survival on anti-PD-1 therapy in lung cancer, where in mouse models alcohol impaired antitumor T-cell responses and increased TIGIT expression, and adding anti-TIGIT largely restored the response to immunotherapy; he noted human data remain limited. In resectable NSCLC, Dr. Eric Singhi relayed Dr. Balazs Halmos's emphasis on early biomarker testing and multidisciplinary review, and Dr. Estela Rodriguez, covering Dr. Jay Lee's #MaTOS26 talk on perioperative chemo-IO, wrote that the shift to induction therapy has happened while identifying who benefits most remains missing.

“Enjoyed presenting the results of the BioNTech mRNA TAA Fixvac phase 1 trial, BNT116 +/- cemiplimab in advanced NSCLC #ENA26 Efficacy signals in 1st line frail pts & post prior PD1, ongoing cohorts including oncogene-driven tumors #LCSM @EORTC @AACR @CancerInstIRE”
— @FordePatrick · BNT116 phase 1 · View post ↗
“Alcohol consumption may also affect the efficacy of immunotherapy. A new study found that regular alcohol use was associated with shorter survival in patients with lung cancer receiving anti-PD-1 therapy. In mouse models, alcohol impaired antitumor T-cell responses, weakened immune memory, and increased TIGIT expression. Interestingly, adding anti-TIGIT largely restored the response to immunotherapy. Human data remain limited, but these findings are worth exploring further.”
— @dr_yakupergun · Alcohol and anti-PD-1 · View post ↗
“@BalazsHalmosMD reminds us that resectable NSCLC is no longer just about surgery first. With expanding biomarker-driven treatment options, the question is increasingly WHO needs treatment, WHAT treatment, & WHEN? The key? Early biomarker testing & MDT.”
— @lungoncdoc · Resectable NSCLC · View post ↗At the ENA26 ADC plenary session in Barcelona on November 19, Dr. Paolo Tarantino reviewed the past, present and future of antibody-drug conjugates alongside Dr. Aditya Bardia, Raffaele Colombo, Dr. Alex Spira and Nicole Biber. Highlighting Raffaele Colombo's talk, Dr. Tarantino noted that most ADCs deliver cytotoxic payloads with substantial cross-resistance (e.g., TOP1i), and that a new generation of ADCs delivering targeted therapies, with KRAS-inhibitor and PI3K-inhibitor ADCs in pole position, is soon to enter clinical development; Dr. Bardia reviewed established ADCs and upcoming bispecific antibody constructs. Also at ENA, Olema Oncology presented preclinical data showing its selective oral KAT6A degraders inhibited proliferation across ER+/HER2- breast cancer models, including ESR1-mutant and wild-type models; these agents are preclinical. Separately, Dr. Yakup Ergün highlighted a 13-patient spatial transcriptomics study suggesting that the spatial distribution of HER2 within the tumor, not only its expression level, may influence response to T-DXd.

“40 years of ADCs: an extraordinary journey, and we’re only getting started! A privilege to review the past, present & future of ADCs at the EORTC-AACR-NCI (ENA) ADC Plenary Session alongside @dradityabardia, @raffcolo, Alex Spira & Nicole Biber. #ENASymp26”
— @PTarantinoMD · ENA26 ADC plenary · View post ↗
“Most ADCs deliver cytotoxic payloads, with substantial cross-resistance (e.g., TOP1i). But a new generation of ADCs delivering targeted therapies may expand our arsenal, with KRASi & PI3Ki ADCs in pole position, soon in clinical development. Great talk by @raffcolo at #ENASymp26!”
— @PTarantinoMD · Next-generation ADC payloads · View post ↗At #ENA26, updated phase 1/2 data for first-line daraxonrasib plus gemcitabine/nab-paclitaxel in metastatic pancreatic cancer (n=61), highlighted by Dr. Yakup Ergün, showed an ORR of 60.7% (CR 8.2%), median PFS of 12.8 months, and 12-month OS of 76.6%. This first-line combination is investigational; daraxonrasib (Rasonque) is FDA approved as monotherapy for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy, and Dr. Wungki Park noted the ongoing phase 3 RASolute 303 will determine whether the combination beats the control arm. In gastroesophageal adenocarcinoma, Merck's phase 3 TroFuse-015 trial of the investigational TROP2-directed ADC sacituzumab tirumotecan (sac-TMT) versus physician's choice chemotherapy in 473 patients after two or more prior lines met its primary endpoint of overall survival, but did not meet PFS by central review; no hazard ratio or medians have been released. Dr. Kohei Shitara said he is looking forward to the full data presentation, Dr. Paolo Tarantino called it yet another ADC improving OS but not PFS in gastric cancer, and Dr. Allan Pereira asked how large the OS benefit is and how an OS win sits with a PFS miss. Dr. Arndt Vogel also shared primary results of the phase IIIb TOURMALINE study in the Journal of Hepatology, showing a shorter durvalumab infusion is feasible with gemcitabine-based chemotherapy in advanced biliary tract cancer.

“First-line daraxonrasib + gem/nab-paclitaxel in metastatic pancreatic cancer (Ph 1/2, n=61): • ORR: 60.7% (CR: 8.2%) • mPFS: 12.8 mo • 12-month OS: 76.6% With standard chemotherapy combinations, ORR is approximately 36–42%, mPFS 5.6–7.4 mi, and mOS 9–11 months. These results are highly promising. The definitive comparison will come from the Phase 3 RASolute 303 trial, but even these early data may herald a major breakthrough in pancreatic cancer. Let's also remember that, although daraxonrasib monotherapy received FDA approval in the second-line setting, it is also approved for first-line use in patients with metastatic disease who are not candidates for multiagent chemotherapy.”
— @dr_yakupergun · 1L daraxonrasib + gem/nab-P · View post ↗
“Phase 3 TROFUSE-015: Sac-TMT, a TROP2-directed ADC, improved OS in 3L+ gastroesophageal adenocarcinoma, but did not meet PFS. Looking forward to the full data presentation and further discussion!”
— @KoheiShitara · TroFuse-015 topline · View post ↗
“Really unusual and unexpected to see such deep response in metastatic PDAC. Glad this combination is well received with manageable safety profile and durable response translating into long survival. This looks very promising! Our ongoing RASolute303 will eventually answer whether it is better than control arm definitively but this looks very promising.”
— @CentralParkWMD · RASolute 303 · View post ↗Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
At #SOGUG26, Dr. Tom Powles relayed Dr. David McDermott's view that the investigational T-cell engager XmAb819 is the most interesting thing in kidney cancer at the moment, noting early renal cancer data look good with more trials to follow. At #IKCSNA26, an overview of the RCC biomarker landscape covered prognostic and predictive markers across IO and VEGFR/HIF-targeted therapy, from IMDC and histology to ctDNA and KIM-1; Dr. Antonio Ocejo framed the challenge as translating these biomarkers into treatment decisions. The meeting also recognized Dr. Wenxin (Vincent) Xu with the Christopher G. Wood Rising Star Award and Dr. Tian Zhang with the Orange Up Impact Award, alongside a Women in RCC breakfast.

“BITE: XmAb819 is ‘The most interesting thing in kidney cancer at the moment’ (according to David McDermott). T cell engagers have a distinct MOA to immune checkpoint inhibition, targeting a different part of the immunity cycle. They are changing ‘colder’ cancers, such as small cell lung and prostate cancer - early renal cancer data looks good - more trials to follow … #SOGUG26 @Annals_Oncology @OncoAlert @montypal @DrChoueiri”
— @tompowles1 · XmAb819 in RCC · View post ↗
“Great overview by @KellyNFitz at #IKCSNA26 on the evolving biomarker landscape in #RCC. A useful framework highlighting how prognostic and predictive biomarkers differ across IO and VEGFR/HIF-targeted therapies—from IMDC and histology to emerging tools like ctDNA and KIM-1. The challenge is translating these biomarkers into treatment decisions!”
— @ja_ocejo · RCC biomarkers · View post ↗A multicenter US Myeloma Immunotherapy Consortium study in Nature Medicine characterized enterocolitis associated with BCMA-directed CAR T-cell therapy (IEC-EC): 39 of 1,308 patients (3.0% including probable cases; 2.2% biopsy-confirmed), median onset about 75 days after infusion, 73% needing IV nutrition, 22% needing ICU care, and 41% dying while it was active (all causes, mostly infection). Dr. Samer Al Hadidi noted this real-world incidence is roughly double the 1.2% seen in clinical trials and that no pretreatment factor predicted it, while Dr. Breno Moreno de Gusmão urged early biopsy for late diarrhea after cilta-cel. The Myeloma Society also highlighted a new global definition of cure: five years in complete remission without treatment, confirmed by highly sensitive testing and imaging.

“Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy #mmsm ➡️~ 2–3 in 100 people treated get IEC-EC. 3% counting probable cases (39 of 1308) and 2.2% counting biopsy confirmed cases only ➡️~1 in 100 (roughly 0.8–1.2%) may die while having IEC-EC ➡️Median is ~ 2.5 months (75 days) after infusion (range: 2 weeks - ~ 18 months (541 days)) 🛑~ 3 in 4 (73%) needed IV nutrition, ~ 1 in 5 (22%) needed ICU care 🛑~ 4 in 10 (41%) died while it was active (that counts all causes, including stroke and parkinsonism) 🛑~1 in 4 patients referred for suspected IEC-EC didn’t have it (12 of 53). Causes were infection, medications, etc.. Also ~ 1 in 3 patients with IEC-EC (37%) had an infection at or before onset 🛑Cause of death with IEC-EC was mostly infection (10 of 17 deaths mostly sepsis or bacteremia) 🛑No pre treatment factor predicted who would get IEC-EC Compared to clinical trials data, the incidence is ~ double (1.2% in studies👇vs. ~2.5% in this RW data and similar previous RW data)”
— @HadidiSamer · CAR-T enterocolitis · View post ↗
“Cilta-cel enterocolitis (IEC-EC), US MM Immunotherapy Consortium (Nat Med): 3.0% of 1,308 pts, median onset day 75. Grade ≥3 diarrhea 85%, TPN 73%; 41% died with active IEC-EC. Late diarrhea after cilta-cel needs early biopsy. #mmsm”
— @morenodegusmao · Cilta-cel IEC-EC · View post ↗Dr. Toby Eyre shared 25-year follow-up of the Nordic MCL2 and MCL3 trials in the British Journal of Haematology, examining long-term relapse dynamics and relative survival after autologous haematopoietic stem cell transplantation for mantle cell lymphoma. The annual GATLA lymphoma meeting also wrapped up.

“Long-term relapse dynamics & relative survival after autologous haematopoietic stem cell transplantation for mantle cell lymphoma: 25-year follow-up of the Nordic MCL2 and MCL3 trials in @BrJHaem #MCL British Journal of Haematology | Wiley Online Library”
— @tobyeyre82 · Nordic MCL 25-year follow-up · View post ↗